(Q39933225)

15 September 2017

title

Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis (English)

1 reference

15 September 2017

Alessandra Verdina

3

0 references

Rossella Galati

object named as

Rossella Galati

9

0 references

Mario Santini

object named as

Mario Santini

6

0 references

Alfonso Baldi

object named as

Alfonso Baldi

8

0 references

author name string

Daniela Stoppoloni

1

1 reference

15 September 2017

Irene Cardillo

2

1 reference

15 September 2017

Bruno Vincenzi

4

1 reference

15 September 2017

Simona Menegozzo

5

1 reference

15 September 2017

Ada Sacchi

7

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

15 September 2017

1 reference

15 September 2017

volume

113

1 reference

15 September 2017

issue

10

1 reference

15 September 2017

page(s)

2761-2769

1 reference

Mechanisms in the Pathogenesis of Asbestosis and Silicosis

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

The role of cyclooxygenases in inflammation, cancer, and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

The molecular basis of asbestos induced lung injury

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Messenger RNA degradation in eukaryotes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

The RNA-binding protein HuR regulates the expression of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

The proximal region of the 3'-untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

HuR and mRNA stability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

The European mesothelioma epidemic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

HuR: post-transcriptional paths to malignancy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23904

7 January 2021

Identifiers

DOI

10.1002/CNCR.23904

1 reference

15 September 2017

1 reference